Every 10-Q that Black Diamond Therapeutics, Inc. (BDTX) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow BDTX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BDTX filings page.
Black Diamond Therapeutics is a clinical-stage oncology company focused on MasterKey therapies such as silevertinib, a fourth-generation EGFR inhibitor for EGFR‑mutant non-small cell lung cancer (NSCLC) and glioblastoma (GBM). For the quarter ended June 30, 2026, it reported a net loss of $9.9 million, or $0.17 per share, versus a $10.6 million loss a year earlier. Six-month results shifted from prior-year net income of $46.0 million, which had included a $70.0 million Servier upfront payment, to a net loss of $18.9 million.
Research and development expense declined to $7.4 million in the quarter and $14.4 million year-to-date, reflecting lower spending on the NSCLC Phase 2 trial and the out-licensed BDTX‑4933 program, partly offset by start-up costs for a Phase 2 GBM trial. General and administrative expense was $4.7 million in the quarter and $8.9 million for six months. Cash, cash equivalents and investments totaled about $110.5 million, with total assets of $125.0 million and stockholders’ equity of $96.1 million, and management currently expects this liquidity to fund operations into the second half of 2028. The Servier license for BDTX‑4933 provides potential milestones of up to $710.0 million plus tiered royalties, while the company also has an at-the-market equity program that has raised $25.0 million gross to date.
Black Diamond Therapeutics, Inc. reported a net loss of $9.0 million for the quarter ended March 31, 2026, compared with net income of $56.5 million a year earlier, when it recorded a $70.0 million upfront license payment from Servier.
Research and development expense declined to $7.0 million from $10.5 million, reflecting lower NSCLC spending and the out‑licensing of BDTX‑4933, partially offset by higher GBM costs. General and administrative expense fell to $4.3 million from $5.0 million due to operational efficiencies.
The company ended the quarter with $118.3 million in cash, cash equivalents and investments and expects this to fund operations into the second half of 2028. Lead EGFR inhibitor silevertinib is in Phase 2 trials for NSCLC and newly diagnosed EGFR‑altered glioblastoma.
Black Diamond Therapeutics (BDTX) reported Q3 2025 results showing a net loss of $8,498, while year-to-date net income reached $37,483 on the back of $70,000 in license revenue recognized from its March agreement with Servier for BDTX-4933. Operating expenses declined, with R&D at $7,437 and G&A at $3,541 in Q3.
Cash, cash equivalents and investments totaled about $135.5 million as of September 30, 2025, and management estimates funding into the fourth quarter of 2027. The balance sheet strengthened: total stockholders’ equity rose to $126,152 from $83,285 at year-end 2024, while current liabilities decreased to $15,545. Shares outstanding were 56,974,913 as of October 30, 2025.
The Servier deal included a $70.0 million upfront payment and eligibility for up to $710.0 million in development and commercial milestones, plus tiered royalties on global net sales. Lead program silevertinib advanced in Phase 2, with initial frontline cohort results targeted for Q4 2025.